Preclinical Pharmacokinetic and Pharmacological Studies
The contract(s) resulting from this procurement will provide a continuing resource for conducting the following typesof studies with agents selected for preclinical development through the programs supported by the Institute: (1) development of sensitive analytical methods to quantify compounds in plasma, urine, tissues, and other biological matrices; (2)plasma stability and protein binding studies, which are conducted at an early stage of compound development toensure proper sample handling and to aid in the interpretation of in vivo studies; (3) pharmacokinetic evaluation oftest compounds following administration to animals by various routes and schedules, including a determination ofbioavailability by various routes; (4) quantification and identification of drug metabolites generated in vivo and invarious in vitro systems (S9 fractions, microsomes, hepatocytes, P450 isoforms, liver slices); and (5) correlation ofcompound effects on putative molecular targets (pharmacodynamic effects) with compound exposures.
